Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsVivek Ramaswamy’s fortune is chiefly tied to his retained equity in Roivant Sciences, the drug-development company he founded in 2014. Roivant built value by advancing experimental medicines through a network of subsidiary companies, completing transactions involving those subsidiaries, and eventually becoming publicly traded. Forbes estimated Ramaswamy’s net worth at $1.8 billion in November 2025, attributing the bulk to Roivant; that is a dated estimate, not an exact current balance sheet.
Roivant was the central wealth engine
After working as a hedge-fund investor, Ramaswamy founded Roivant in 2014. Its strategy was to acquire drug candidates that larger pharmaceutical companies had partly developed or deprioritized, then advance them through specialized subsidiary companies. The structure let Roivant focus on individual development programs while building a broader portfolio of potential medicines. Forbes described the company’s model and history in 2021.
That model could create value in more than one way: a candidate might advance toward approval, or a subsidiary and its assets could become part of a corporate transaction. It did not depend on one blockbuster drug. As of Forbes’ 2021 account, Roivant had backed more than 40 therapies, while two medicines had received FDA approval. Those are historical figures, not a current count of its pipeline or approvals. Drug development also brought substantial risk: the same account noted that Axovant’s high-profile Alzheimer’s candidate failed a late-stage trial. Forbes’ 2021 report covers both the portfolio and that setback.
Corporate transactions and a public listing made equity valuable
In 2019, Sumitomo Dainippon Pharma struck a transaction involving five Roivant subsidiaries and bought more than 10% of Roivant shares. Forbes reported that the deal allowed some early investors to realize value. It illustrates how Roivant’s subsidiary-based strategy could produce corporate and investment outcomes in addition to the eventual success or failure of individual drug candidates. Forbes’ account of the transaction.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →#1 Best Overall
Roivant went public through a merger with a special-purpose acquisition company (SPAC) in 2021. The announced transaction valued Roivant at $7.3 billion. That was a historical company-level transaction valuation—not the value of Ramaswamy’s personal stake, cash proceeds he received, or his net worth. Public trading gave investors a market in Roivant shares, making the value of an owner’s retained shares more visible and capable of changing with the market. Forbes reported the SPAC deal and its announced valuation.
Most of the reported fortune is tied to shares, not necessarily cash
Forbes estimated Ramaswamy’s net worth at $1.8 billion in November 2025 and said his Roivant stake made up the bulk of it. This is a third-party estimate at a stated point in time; it is not a disclosed balance sheet or an exact October 2026 figure. Forbes’ profile and estimate.
A shareholding can be worth a large amount on paper without having been converted to cash. Ramaswamy has sold some Roivant shares: Axios reported that he sold three million shares for about $33 million in January 2024, and a spokesperson said some proceeds would fund his campaign. That sale turned part of his equity into cash; it was not the origin of the underlying value of Roivant or of his retained stake. Axios’ report on the January 2024 sale.
SEC filings show ownership snapshots, not net worth
Regulatory filings offer dated share counts, but they should not be mistaken for a full personal balance sheet. A May 6, 2026 Schedule 13G reported that Ramaswamy beneficially owned 25,534,970 Roivant common shares, or 3.6% of the class. The filing explicitly excluded 13,357,857 shares held solely by his spouse. These figures describe reported ownership for that filing and date; they do not establish the value of all household assets or liabilities. SEC Schedule 13G filed May 6, 2026.
A December 2025 Form 4 shows why dates and ownership categories matter: after the listed transactions, it reported 33,653,755 directly held common shares and separately listed 13,357,857 shares held indirectly through his spouse. A later filing can reflect exercises, sales, settlements, or other changes, and it may classify direct and indirect holdings differently. A share count from one filing should not be multiplied by a share price from another date and presented as net worth. SEC Form 4 filed December 15, 2025.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Other ventures are part of his profile, but not the main documented source
Ramaswamy has also been associated with Strive and is the author of the 2021 bestseller Woke, Inc. Those activities contribute to his public business profile, but the cited reporting does not establish them as the principal source of his wealth. Forbes identifies Roivant as the bulk of his fortune. Forbes’ wealth profile and Forbes’ 2023 career coverage.
Quick Recap
Best Value
Rank #4
How the pieces fit together
- Business value: Roivant assembled and advanced drug-development assets through subsidiaries, with potential value arising from clinical progress and company-level transactions.
- Equity value: Ramaswamy’s retained ownership in Roivant is the main documented link between the company’s value and his fortune.
- Liquidity: A stock sale can turn some holdings into cash, but it is distinct from the value of shares still held.
- Estimated net worth: Forbes’ November 2025 figure is a dated estimate of overall wealth, not a number directly disclosed by SEC filings.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
